Related by context. All words. (Click for frequent words.) 85 Phase III Clinical Trial 84 Phase 2b Clinical Trial 82 Pivotal Trial 82 Meets Primary Endpoint 81 Clinical Trial Results 81 Phase III Trial 81 Pivotal Clinical Trial 81 Completes Enrollment 80 Phase IIb Trial 80 Patient Enrollment 80 Completes Patient Enrollment 80 Drug Candidate 80 Phase IIb Clinical Trial 80 Phase III Trials 79 Pivotal Phase 79 Receives Orphan Drug Designation 79 Pivotal Phase III 79 Phase 2a Clinical Trial 78 Improves Survival 78 Phase III Clinical Trials 78 Pivotal Trials 78 JAK Inhibitor 78 Investigational Compound 78 II Clinical Trial 78 Preclinical Data 77 Patients Treated With 77 Files IND 77 Adjuvant Treatment 77 Study Evaluating 77 Phase 2b Trial 77 Initiates Clinical Trial 77 Combination REOLYSIN R 77 Initiates Clinical 77 Trial Evaluating 76 NDA Submission 76 FDA Approvals 76 Demonstrates Positive 76 Presents Preclinical Data 76 Prolongs Survival 76 Phase 2a Trial 76 Clinical Trial Evaluating 76 Presents Positive 76 FDA Accepts 76 Previously Treated 76 Study Showed 76 Single Dose 76 Antitumor Activity 76 Phase 2b Study 76 Initiate Clinical Trial 76 Initiates Enrollment 76 Initiate Phase 76 Pooled Analysis 76 Initiates Phase II 76 Dose Ranging Study 76 Efficacy Trial 75 Achieves Primary Endpoint 75 Advanced Melanoma 75 First Patient Enrolled 75 Randomized Clinical Trial 75 Novel Oral 75 Granted Orphan Drug 75 Personalized Immunotherapy 75 Investigational Treatment 75 Present Preclinical Data 75 Lupus Drug 75 Investigational Drug 75 Expanded Indication 75 Phase IIa Clinical Trial 75 Demonstrates Significant 75 IND Application 75 Improves Outcomes 75 FDA Clears 75 Severe Sepsis 75 Long Term Efficacy 74 Monotherapy 74 First Patient Dosed 74 Oral Calcitonin 74 Phase 1b Clinical Trial 74 Initiates Clinical Trials 74 Patients Enrolled 74 Prospective Randomized 74 Hormone Refractory Prostate Cancer 74 Combination Treatment 74 Shows Promising 74 Receives Positive Opinion 74 Investigational Agent 74 Confirmatory Phase 74 Vicriviroc 74 Improved Survival 74 Anticancer Drug 74 Randomized Study 74 Initiates Phase III 74 Demonstrates Potent 74 Commences Phase 74 Shows Efficacy 74 Successfully Completes Phase 74 Metastatic Colorectal Cancer 74 Drug Fails 74 Receives Orphan Drug 74 SPRYCEL ® 74 Oral Fingolimod 74 Ranolazine 74 Patients Treated 74 Relapsed Multiple Myeloma 73 Anti Tumor Activity 73 Metastatic Prostate Cancer 73 Receives Approvable Letter 73 Survival Benefit 73 Tyrosine Kinase Inhibitor 73 Submits NDA 73 Pharmacokinetic Study 73 Phase 2a Study 73 PRN FDA Approves 73 Monoclonal Antibody 73 Lung Cancer Trial 73 Plus Ribavirin 73 Drug Shows Promise 73 Rheumatoid Arthritis Patients 73 Investigational Oral 73 Announces FDA Clearance 73 Patient Enrolment 73 Preclinical Study 73 Randomized Phase 73 Relapsed Refractory 73 Hsp# Inhibitor 73 First Patient Treated 73 Receives FDA Clearance 73 Psoriasis Drug 73 Clinical Study 73 Gout Drug 73 Renal Cell Carcinoma 73 Lung Cancer Drug 73 Anti Tumor 73 Previously Untreated 73 Aflibercept 72 Statistically Significant 72 Lupus Nephritis 72 IND Filing 72 Begins Dosing 72 Newly Diagnosed Multiple Myeloma 72 Patients Receiving 72 Presents Preclinical 72 Medoxomil 72 Prostate Cancer Patients 72 Chronic Hepatitis C 72 Pulmonary Arterial Hypertension 72 Molecular Diagnostic Test 72 HDAC Inhibitor 72 Cholesterol Lowering Drug 72 Tezampanel 72 Ofatumumab 72 Autologous Stem Cell Transplantation 72 FDA Okays 72 Collaborators Present 72 Protease Inhibitor 72 Kinase Inhibitor 72 Proven Effective 72 Metastatic Melanoma 72 Significantly Improved 72 Epratuzumab 72 Well Tolerated 72 Novel Antibiotic 72 Multiple Myeloma Patients 72 Adjunctive Therapy 72 Study Demonstrates 72 Treated Patients 72 HCV Protease Inhibitor 72 Elagolix 72 Complicated Skin 72 Arthritis Drug 72 Milestone Payment 72 Rotavirus Vaccine 72 Interferon Beta 72 Gets FDA Clearance 72 Rheumatoid Arthritis Drug 72 Demonstrates Potential 72 Treatment Naïve 72 Phase III Pivotal 72 Nicotine Vaccine 72 FDA APPROVES 72 Vaccine Adjuvant 72 Commence Phase 72 Files Investigational 72 Anticancer Agent 72 Generic Version 72 IIa Clinical Trial 72 Advanced Colorectal Cancer 72 Prostate Cancer Vaccine 71 Microplasmin 71 Osteoporosis Drug 71 Bosutinib 71 Eluting Stent 71 Recombinant Human 71 Controlled Study 71 Improve Survival 71 Epilepsy Drug 71 Hematological Malignancies 71 Cypher Sirolimus 71 FDA Approves 71 Phase III Pivotal Trial 71 Transdermal Patch 71 Antiviral Activity 71 Initiates Phase 71 Augment TM 71 Initiate Phase III 71 Is Well Tolerated 71 Xcytrin R 71 MEK Inhibitor 71 Fast Track Status 71 Intravenous Formulation 71 Initiates Phase 2b 71 Receives Milestone Payment 71 phase IIb trial 71 Significantly Improves 71 Kidney Transplant Patients 71 HER2 Positive Breast Cancer 71 Chronic Hepatitis B 71 Migraine Drug 71 Dose Escalation 71 Resistant Hypertension 71 Biomarker Study 71 Phase IIa Trial 71 Cutaneous T 71 Proves Effective 71 R lenalidomide 71 Bazedoxifene 71 Myeloma Patients 71 Adjuvant Therapy 71 Ozarelix 71 Metastatic Renal Cell Carcinoma 71 Phase Ib Clinical Trial 71 Reports Preclinical Data 71 Spectrum Pharmaceuticals Announces 71 Pediatric Patients 71 Combination Therapy 71 Acute Ischemic Stroke 71 Announces Poster Presentations 70 Novel Inhibitor 70 Antitumor 70 Telbivudine 70 Develop Novel 70 Relapsing Remitting Multiple Sclerosis 70 Sirolimus Eluting Stent 70 Parathyroid Hormone 70 Novel Compound 70 FDA Clearance 70 Humanized Anti 70 Advanced Prostate Cancer 70 Peginterferon 70 Eculizumab 70 Double Blind Placebo 70 Embolic Protection 70 Glatiramer Acetate 70 Systemic Delivery 70 FOLOTYN ® 70 Hepatocellular Carcinoma 70 Enrolls First 70 Completes Patient Enrolment 70 JAK2 Inhibitor 70 Patent Covering 70 BioSante Pharmaceuticals Announces 70 Interferon Alpha 70 Overactive Bladder 70 Acute Attacks 70 Cell Lymphoma 70 NAVISTAR R 70 Data Suggest 70 Treatment Experienced 70 Significantly Reduced 70 Hepatitis C Patients 70 Testosterone Gel 70 Randomized Double Blind 70 Submits Biologics License Application 70 Stent Restenosis 70 Fondaparinux 70 Romidepsin 70 Begins Clinical Trial 70 Mylan Receives Approval 70 Platelet Inhibition 70 Low Dose 70 Disease Progression 70 Significantly Reduces 70 Valsartan 70 Oral Insulin 70 Topline Results 70 vapreotide acetate 70 Cholesterol Drug 70 Orphan Status 70 Universal Flu Vaccine 70 Patients Suffering 70 Elderly Patients 70 Pafuramidine 70 Clinical Efficacy 70 Infected Patients 70 Demonstrates Efficacy 70 Appears Safe 70 Controlled Trial 70 Naive Patients 70 Seasonal Influenza Vaccine 70 Patients Undergoing 70 Hypertensive Patients 70 Nebulized 70 Receptor Agonist 70 Initiated Phase 69 Confirms Efficacy 69 Clinical Trial Data 69 Announces Initiation 69 Aliskiren 69 Dasatinib 69 Endeavor Drug Eluting 69 Sustained Efficacy 69 Antibody Drug Conjugate 69 Renal Cancer 69 Advanced Renal Cell 69 Lung Cancer Patients 69 oral prodrug 69 Generic Versions 69 TM Drug Eluting 69 Reveals Positive 69 Chronic Myeloid Leukemia 69 Phase IIIb 69 Sapacitabine 69 STELARA TM 69 Announce License Agreement 69 Placebo Controlled Trial 69 PDUFA Date 69 Osteoporosis Treatment 69 Clinical Outcome 69 Fungal Infections 69 Disease Modifying 69 Unfractionated Heparin 69 Shows Promise 69 Drug Coated Stent 69 Therapeutic Vaccine 69 Clinical Study Shows 69 Zenvia Phase III 69 Prophylactic Treatment 69 Efficacy Results 69 Neoadjuvant Chemotherapy 69 HER2 Positive 69 Phase Ib II 69 Heart Failure Patients 69 Presents Positive Preclinical 69 Immunomedics Announces 69 Myelodysplastic Syndromes 69 Drug Resistant 69 Receives Fast Track 69 Preclinical Efficacy 69 Demonstrate Significant 69 Dapagliflozin 69 Drug Eluting 69 Mouse Model 69 Irinotecan 69 Pivotal Phase II 69 Drug Eluting Stent 69 Brentuximab Vedotin SGN 69 Anticancer Activity 69 Aurora Kinase 69 fosbretabulin 69 Inhaled Insulin 69 IL# PE#QQR 69 Sirolimus Eluting 69 Telaprevir VX 69 Peginterferon Alfa 2a 69 Beta Blocker 69 Randomized Phase II 69 non nucleoside inhibitor 69 Chronic Sinusitis 69 Inhalation Solution 69 Refractory Angina 69 Hepatitis B Vaccine 69 Hemodialysis Patients 69 RNAi Therapeutic 69 Gastric Cancer 69 PEGylated Fab fragment 69 Breast Cancer Recurrence 69 Adjuvant Chemotherapy 69 Earns Milestone Payment 69 Shows Promise Against 69 Atypical Hemolytic Uremic Syndrome 69 Colorectal Cancer Patients 69 Xelox 69 Chronic Heart Failure 69 Patient Treated 69 Novel Treatments 69 Soft Tissue Sarcoma 69 Pertuzumab 69 Diabetic Nephropathy 69 Shows Statistically Significant 69 Mycophenolate Mofetil 68 Orally Active 68 Multicenter Randomized 68 Inhaled Corticosteroids 68 Demonstrated Significant 68 Oral Formulation 68 Zoledronic Acid 68 Catheter Ablation 68 Romiplostim 68 Lung Cancer Survival 68 Enzyme Replacement Therapy 68 Clinical Trial 68 Ocrelizumab 68 Begin Clinical Trials 68 Supplemental Biologics License Application 68 Tigecycline 68 Interferon Alfa 68 NICE Recommends 68 TO AVOID PREGNANCY WHILE 68 Targeted Therapy 68 PHASE III 68 Secondary Hyperparathyroidism 68 Cardiotoxicity 68 Randomized Trials 68 Patient Outcomes 68 Intravitreal 68 Subgroup Analysis 68 Relapsing Multiple Sclerosis 68 Effectively Treats 68 Zorbtive TM 68 Pharmacokinetics PK 68 Potent Antiviral Activity 68 Milestone Payments 68 Left Ventricular 68 ISTODAX ® 68 Demonstrates Sustained 68 Vascular Disrupting Agent 68 MKC# MT 68 Multicenter 68 Small Molecule 68 Blood Pressure Drug 68 Treatment Resistant 68 Plaque Psoriasis 68 Immunotherapeutic 68 Nilotinib 68 Myocet 68 Phase IIIb clinical 68 Dry Powder Inhaler 68 Iloperidone 68 Polymerase Inhibitor 68 multicenter Phase III 68 initiated Phase Ib 68 Balloon Angioplasty 68 Follicular Lymphoma 68 Treatment Naive Patients 68 atypical Hemolytic Uremic Syndrome 68 Positive Opinion 68 Oral Mucositis 68 Advanced Pancreatic Cancer 68 R bendamustine hydrochloride 68 Randomized Evaluation 68 Tumor Targeting 68 Omacetaxine 68 Daclizumab 68 ENDEAVOR IV 68 Treatment Reduces 68 Kinase Inhibitors 68 acute peripheral arterial 68 Acute Myocardial Infarction 68 Submits IND 68 Augment ™ 68 Taro Receives 68 Sangamo BioSciences Announces 68 Aloxi ® 68 Knee Osteoarthritis 68 Synthetic Peptide 68 Glufosfamide 68 Antiplatelet 68 Acute Heart Failure 68 Eluting Coronary Stent System 68 Dupuytren Contracture 68 Receive Milestone Payment 68 Chronic Lymphocytic Leukemia CLL 68 PROMUS R 68 Demonstrates Statistically Significant 68 Preclinical Models 68 SinuNase TM 68 ORENCIA ® 68 Randomized Clinical Trials 68 Schizophrenia Treatment 68 Efficacious 68 Vitro Activity 68 Hospital Acquired Pneumonia 68 Safinamide 68 RNAi Therapeutics 68 receptor tyrosine kinase inhibitor 68 Bare Metal Stents 68 dual endothelin receptor antagonist 68 GATTEX TM 68 Teva Provides Update 68 Therapeutic Antibody 68 Milestone Payment From 68 adalimumab Humira 68 Diabetic Neuropathy 68 dependent kinase inhibitor 68 lexidronam injection 68 Regenerative Cells 68 Multicenter Study 68 Castration Resistant Prostate Cancer 68 Announces Tentative Approval 68 Panzem R 68 Peripheral Arterial 67 sunitinib Sutent 67 Anthracycline 67 evaluating tivozanib 67 BioElectronics Announces 67 investigational humanized monoclonal antibody 67 Diffuse Large B 67 Randomized Double Blind Placebo 67 Anticancer Compound 67 Drug Eluting Coronary Stent 67 Peginterferon alfa 2b 67 Schizophrenia Drug 67 Infarct 67 MKC# MKC# PP 67 metastatic malignant 67 Carotid Stenting 67 catheter occlusion 67 PANVAC VF 67 Amrubicin 67 Inhalation Aerosol 67 Complete Remission 67 Refractory Hodgkin Lymphoma 67 Clolar ® 67 Multiple Ascending Dose 67 Malignant Melanoma 67 Archexin 67 TRANSFORMS 67 Completes Dosing 67 Tumor Response 67 Nuvelo Announces 67 Cethromycin 67 Cites Positive 67 Hormone Receptor Positive 67 Randomized Double blind 67 Licenses Novel 67 Azacitidine 67 5 fluorouracil leucovorin 67 Sagent Pharmaceuticals Announces 67 Node Positive 67 Neulasta R 67 Pegylated Interferon 67 Gene Therapy Trial 67 Intravascular 67 Targeted Therapies 67 Benign Prostatic Hyperplasia 67 Interferon Gamma 67 refractory chronic lymphocytic 67 Protease Inhibitors 67 Melphalan 67 Therapy Evaluation 67 Cetuximab Erbitux 67 Initiate Phase II 67 CD# CEA 67 Non Invasive Treatment 67 Slow Progression 67 Blinatumomab 67 Degarelix 67 Diabetic Patients 67 Pirfenidone 67 mGluR5 negative 67 Contrast Agent 67 Tolerability 67 Metabolic Efficiency 67 Denufosol 67 PROSTASCINT R 67 Antifungal 67 FDA Approvable Letter 67 Vildagliptin 67 Methylnaltrexone 67 Epidermal Growth Factor Receptor 67 Chemoradiation 67 Successfully Treated 67 Improve Outcomes 67 Tumor Growth 67 Muraglitazar 67 Thrombectomy 67 Ciclesonide 67 dasatinib Sprycel 67 Golimumab 67 Submits Investigational 67 Aneurysm Repair 67 beta 1a 67 Maleate 67 REG1 Anticoagulation System 67 ANDA Filing 67 Daptomycin 67 Sustained Reduction 67 Treating Chronic 67 Myelodysplastic Syndrome MDS 67 Vascular Grafts 67 Postmenopausal Women 67 Antigen Specific 67 CYPHER R Sirolimus Eluting 67 Receives Complete Response 67 Chronic Lymphocytic Leukemia 67 Fluconazole 67 Receives SFDA Approval 67 Paclitaxel Carboplatin 67 APEX PD 67 Ovarian Cancer Patients 67 Multicenter Trial 67 Replacement Therapy 67 Renal Artery 67 Commercialize 67 Treatment Naïve Patients 67 Ridaforolimus 67 Stem Cell Treatment 67 Anti Inflammatory Drug 67 Maribavir 67 Liver Failure 67 Submits Supplemental 67 Resubmission 67 Onyx Pharmaceuticals Announces 67 GOUT 67 Less Invasive 67 Kidney Function 67 Tesetaxel 67 Novel Therapeutic 67 Systemic Sclerosis 67 Companion Diagnostic 67 Skeletal Muscle 67 AVASTIN 67 Receives CE Marking 67 PEG IFN 67 Emerging Therapies 67 Neoadjuvant 67 Shown Effective 67 XYOTAX TM 67 Asthma Treatment 67 phase IIa 67 Marketing Authorisation Application 67 5 FU leucovorin 67 induced macular edema 67 Phase 1b clinical trials 67 TKB# 67 Anti CD# Antibody 67 Sign Licensing Agreement 67 Antimicrobial Coating 67 Million Milestone Payment 67 BRIM2 67 dasatinib Sprycel ® 67 Radical Prostatectomy 67 Drug Prevents 67 ALVESCO ® 67 Diabetic Foot Ulcer 67 Receptor Antagonist 67 TAXUS ATLAS 67 Brain Metastases 67 Obtains FDA 66 Anemia Drug 66 Kamada AAT 66 R Saizen R 66 Stent Implantation 66 Recurrent Breast Cancer 66 Weight Loss Drug 66 Combination Clinical Trial 66 Hypercholesterolemia 66 Therapeutic Competitors Companies 66 Bepreve TM 66 Controlled Clinical Trial 66 Dalbavancin 66 Patient Accrual 66 Successfully Treats 66 TELINTRA R 66 Cardiovascular Outcomes 66 Sirolimus eluting 66 Tipranavir 66 miconazole Lauriad ® 66 Placebo Controlled 66 Showed Significant 66 methylnaltrexone bromide 66 Nucleoside 66 Pemetrexed 66 Adenoma 66 Camptosar ® 66 TAXUS Element Paclitaxel Eluting 66 Civacir 66 Statin Therapy 66 TNF Tumor Necrosis Factor 66 Bipolar Depression 66 Neulasta ® 66 Vaccine Candidate 66 monoclonal antibody conjugated 66 See CLINICAL PHARMACOLOGY 66 Boceprevir 66 Feasibility Trial 66 Trastuzumab DM1 66 targeted radiotherapeutic 66 Enrolling Patients 66 Acute Decompensated Heart Failure 66 AFREZZA TM 66 Percutaneous Tibial Nerve Stimulation 66 Oral Cladribine 66 Novel Mechanism 66 myelodysplastic myeloproliferative diseases 66 Beneficial Effects 66 Gliadel R 66 Receives Marketing Authorization 66 Endometrial Cancer 66 Blood Thinner 66 Tiotropium 66 Myoblast 66 Anti Clotting Drug 66 Hepatitis C Genotype 66 Pegylated Liposomal Doxorubicin 66 phase IIb clinical 66 Dose Finding 66 Seasonal Allergic Rhinitis 66 Circulating Tumor Cells 66 Calcium Acetate 66 Cardiac Resynchronization Therapy 66 CYT# potent vascular disrupting 66 Platinol ® 66 generation purine nucleoside 66 ritonavir boosted 66 Aztreonam Lysine 66 Ischemic Stroke 66 Paroxysmal Atrial Fibrillation 66 Toremifene 66 Ziprasidone 66 Fabry Disease 66 ABLYNX 66 Inflammatory Markers 66 PEGylated anti 66 ARIXTRA R 66 Drug Combo 66 FOLFOX6 chemotherapy regimen 66 Meta Analysis 66 Kit CD# positive 66 FUSILEV ® 66 Bronchodilator 66 Immunosuppressant 66 Initiates Dosing 66 Cell Transplants 66 Combo Therapy 66 Hedgehog Pathway Inhibitor 66 Non Inferiority 66 Carboplatin Paclitaxel 66 Ecallantide 66 Tuberculosis Vaccine 66 Chemotherapy Regimen 66 Heart Transplant Recipients 66 imatinib Gleevec ® 66 Bortezomib 66 Inflammatory Arthritis 66 Submits Application 66 ZEVALIN ® 66 Contrast Agents 66 Treatment Regimen 66 pralatrexate injection folate analogue 66 rilonacept 66 Submits Response 66 VIVUS Announces 66 Immunosuppression 66 Pegylated 66 Acute Migraine 66 Bioresorbable 66 Drug Eluting Stent System 66 registrational trial 66 docetaxel Taxotere ® 66 Optimer Pharma 66 Clinical Evaluation 66 virus HCV protease inhibitor 66 Dose Response 66 Immunogenicity 66 Predict Risk 66 Oral Interferon 66 Antiarrhythmic 66 Reduces Risk 66 Cloretazine ® 66 oncolytic virus therapies 66 Metabolic Disorder 66 Temsirolimus 66 Fluorouracil 66 Mg Usa 66 alfa 2a 66 Cetrorelix 66 ORENCIA R 66 including eniluracil ADH 66 Bivalirudin 66 Sipuleucel T 66 Dual Antiplatelet Therapy 66 Bucindolol 66 Antiviral Drugs 66 Wafer polifeprosan 66 Levoleucovorin 66 Breast Cancer Treatment 66 BARACLUDE R 66 Tacrolimus 66 Interferon beta 1a 66 Venous Thromboembolism 66 Kidney Transplant Recipients 66 Therapy Improves 66 Cinacalcet 66 Reports Positive 66 pan HDAC inhibitor 66 Recurrent Glioblastoma 66 GW# [003] 66 Lanthanum Carbonate 66 Phase IIIb study 66 Fulvestrant 66 Inhibits 66 TM Everolimus Eluting 66 Diabetic Macular Edema 66 Diabetic Ulcers 66 antibody MAb 66 Reduced Incidence 66 Lowers Risk 66 Pazopanib 66 Cardiovascular Events 66 Partial Onset Seizures 66 Hematological Cancers 66 Second Pivotal Phase 66 Fixed Dose 66 Fracture Risk 66 Bevacizumab 66 Total Knee Arthroplasty 66 Balloon Catheters 66 Bone Metastases 66 Deforolimus 66 MIVI III 66 TRANSDUR ™ 66 Orphan Drug Status 66 lumiliximab 66 Fludarabine 66 Atopic Dermatitis 66 Abbott HUMIRA 66 Renal Impairment 66 Androgen Deprivation Therapy 66 WorldHeart Announces 66 Chemotherapy Improves 66 Dose Ranging 66 Immunogenic 66 Prodrug 66 Prostate AdenoCarcinoma Treatment 66 Non Invasive 66 novel histone deacetylase 66 mapatumumab 66 Versus Placebo 66 Begins Shipment 66 BAL# [002] 66 Observational Study 66 Topical Cream 66 Phase III Psoriasis 66 C1 Inhibitor 66 Pegloticase 66 Surgical Sealant 66 Oncology Compounds 66 Therapeutic Potential 66 Bone Mineral Density 66 Potent Inhibitor 66 Poniard Pharmaceuticals Announces 66 Hepatic Encephalopathy 66 etanercept Enbrel 66 Primary Endpoint 66 brand ciclesonide HFA 66 Neuroprotective Effects 66 Implantable Device 66 Desvenlafaxine Succinate 66 ALN HPN 66 Generic Version Of 66 aripiprazole Abilify 66 Gastrointestinal Disorders 66 Tesamorelin 66 Treatment Shows Promise 65 Abstract Accepted 65 Panzem R NCD 65 PDX pralatrexate 65 liposomal formulation 65 Treatment Naive 65 Vaccine Protects Against 65 Osteoarthritis Patients 65 Fludara ® 65 Erectile Dysfunction Drug 65 ThermoDox R 65 Tocilizumab 65 Cerebril TM 65 Syncria R 65 topically applied SEPA 65 Symptom Relief 65 Surgical Mesh 65 KRN# 65 R roscovitine CDK cyclin 65 Solazed TM 65 Nanoemulsion 65 Febuxostat 65 5 Fluorouracil 65 CCX# B 65 Rigel R# 65 Placebo Controlled Study 65 Prognostic Significance 65 acyclovir Lauriad R 65 Inhaled Liposomal Ciprofloxacin 65 trastuzumab Herceptin R 65 Osteoporosis Drugs 65 Drug Eluting Stents 65 Cilostazol 65 Post Operative 65 Study Shows Significant 65 TLK# 65 Anticancer Drugs 65 Liposomal 65 multicenter multinational 65 Immune Responses 65 Oral Anticoagulant 65 Renal Function 65 INCB# [001] 65 MGd 65 Severe Asthma 65 Premature Infants 65 ® lenalidomide 65 Flamel Technologies Announces 65 orally administered inhibitor 65 atazanavir sulfate 65 Gastrointestinal Stromal Tumors 65 Topical Treatment 65 Solid Tumors 65 MyVax R 65 Multicenter Phase 65 mTOR inhibitor 65 Intracranial Aneurysms 65 lucinactant 65 albiglutide 65 Angiogenic 65 dextromethorphan quinidine 65 Prospective Multicenter 65 Randomized Controlled 65 MKC# 65 Immunomodulatory 65 Postmenopausal Osteoporosis 65 PROMUS TM 65 novel VDA molecule 65 Relapsed 65 Alvine Pharmaceuticals 65 Agonist MABA program 65 Albuferon TM 65 LibiGel ® 65 Launches Generic Version 65 Phase Ib clinical 65 PEGINTRON TM 65 thalidomide Thalomid 65 Allergic Rhinitis 65 Tramiprosate ALZHEMED TM 65 pharmacokinetic PK study 65 Predict Response 65 Silodosin 65 Critical Limb Ischemia 65 hypereosinophilic syndrome 65 ceftazidime 65 Xeloda ® 65 Valopicitabine NM# 65 Receives CE 65 Conjugate 65 ACE Inhibitors 65 Angiotensin Converting Enzyme 65 INSPIRE Trial Phase III 65 intranasal formulation 65 Montelukast 65 Prostate Cancer Treatment 65 Regeneron Pharma 65 Carotid Endarterectomy 65 Pandemic Influenza Vaccine 65 Kepivance 65 Relapsed Refractory Aggressive 65 Obese Patients 65 Receives Tentative Approval 65 Radiofrequency Ablation RFA 65 Clostridium difficile Infection 65 REVLIMID R 65 Elotuzumab 65 Bone Graft 65 Epoetin Alfa 65 molecular imaging radiopharmaceutical 65 Prognostic Value 65 Radioimmunotherapy 65 Iluvien ® 65 Metabolic Disease 65 Glaucoma Treatment 65 Transcatheter 65 LymphoStat B TM 65 Adalimumab 65 Corautus Genetics 65 Nasdaq HALO 65 lintuzumab SGN 65 Minimally Invasive Procedure 65 Significantly Increases 65 IMA# 65 Vertebral Fracture 65 RANK Ligand inhibitor 65 Endovascular Treatment 65 gefitinib Iressa 65 Increases Risk 65 Viral Load 65 Myocardial Infarction Study 65 Extended Release 65 Granulocyte Colony Stimulating Factor 65 Hernia Repair 65 Tanespimycin 65 Mouse Models